Quantrx Biomedical (Quantrx Biomedical) ROCE % : 0.00% (As of Sep. 2022)

View and export this data going back to . Start your Free Trial

What is Quantrx Biomedical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Quantrx Biomedical's annualized ROCE % for the quarter that ended in Sep. 2022 was 0.00%.

Quantrx Biomedical ROCE % Historical Data

The historical data trend for Quantrx Biomedical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantrx Biomedical ROCE % Chart

Quantrx Biomedical Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

ROCE %

Get a 7-Day Free Trial

Quantrx Biomedical Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Quantrx Biomedical ROCE % Calculation

Quantrx Biomedical's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	-0.043	/	( ( (0.055 - 2.436)	+	(0.006 - 2.647) )	/ 2 )
	=	-0.043	/	( (-2.381	+	-2.641)	/ 2 )
	=	-0.043	/	-2.511
	=	1.71 %

Quantrx Biomedical's ROCE % of for the quarter that ended in Sep. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	-0.028	/	( ( (0.005 - 2.784)	+	(0.005 - 2.846) )	/ 2 )
	=	-0.028	/	( ( -2.779	+	-2.841 )	/ 2 )
	=	-0.028	/	-2.81
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

Quantrx Biomedical (OTCPK:QTXB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Quantrx Biomedical ROCE % Related Terms

Thank you for viewing the detailed overview of Quantrx Biomedical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Quantrx Biomedical (Quantrx Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quantrx Biomedical Corp (OTCPK:QTXB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

10190 SW 90th Avenue, Tualatin, OR, USA, 97062

Website

http://www.quantrx.com

Quantrx Biomedical Corp operates towards the development and commercialization of patented mini form pad (PAD) based products. The PAD products are based on the company's non-woven disposable absorbent pad technology and it is involved in the PAD-based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its platforms include inSync(R), Unique(TM), and OEM branded over-the-counter and laboratory testing products.

Executives

Michael S Abrams	director	64 RAMSHEAD ROAD, RAYNHAM MA 02767
Patrick T Mooney	director	C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Robert G. Pinco	director	1700 K STREET NW, SUITE 300, WASHINGTON DC 20006
Hayes Arthur H Jr	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Matthew Balk	10 percent owner	229 WEST 60TH STREET, NEW YORK NY 10023
Evan Levine	director, 10 percent owner	1517 SAN JACINTO ST., HOUSTON TX 77002
Hayes Arthur Hull Jr	director	C/O QUANTRX BIOMEDICAL CORPORATION, 100 S. MAIN STREET, SUITE 300, DOYLESTOWN PA 18901
Cindy Horton	officer: V.P. of Diagnostics	209 BRITTANY PARK, ANDERSON SC 29621
Sasha Afanassiev	officer: Officer	120 GARRISON COURT, LANGHORNE PA 19047
Shalom Hirschman	officer: Officer	5240 BLACKSTONE AVENUE, RIVERDALE NY 10471
William H Fleming	director, officer: Secretary
Walter W Witoshkin	director, officer: President and CEO	321 NORRISTOWN ROAD, SUITE 230, AMBLE PA 19002
Mark Capital Llc	10 percent owner	5173 SEAGROVE PLACE, SAN DIEGO CA 92130
Sherbrooke Partners, Llc	10 percent owner	570 LEXINGTON AVENUE, FLOOR 3, NEW YORK NY 10022
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282

Quantrx Biomedical (Quantrx Biomedical) Headlines

No Headlines